Authors: Mainwaring, PN Cunningham, D Gregory, W Hoskin, P Hancock, B Norton, AJ MacLennan, K Smith, P Hudson, GV Linch, D

Citation: Pn. Mainwaring et al., Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen forpatients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdfiaCEBO versus PMitCEBO, BLOOD, 97(10), 2001, pp. 2991-2997

Authors: Buckley, JG MacLennan, K

Citation: Jg. Buckley et K. Maclennan, Cervical node metastases in laryngeal and hypopharyngeal cancer: A prospective analysis of prevalence and distribution, HEAD NECK, 22(4), 2000, pp. 380-385

Authors: Buckley, JG MacLennan, K

Citation: Jg. Buckley et K. Maclennan, Cancer spread in the larynx: A pathologic basis for conservation surgery, HEAD NECK, 22(3), 2000, pp. 265-274

Authors: Adams, J Carder, PJ Downey, S Forbes, MA MacLennan, K Allgar, V Kaufman, S Hallam, S Bicknell, R Walker, JJ Cairnduff, F Selby, PJ Perren, TJ Lansdown, M Banks, RE

Citation: J. Adams et al., Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen, CANCER RES, 60(11), 2000, pp. 2898-2905

Authors: Humphrey, G Hazel, DL MacLennan, K Lewis, I

Citation: G. Humphrey et al., Expression of CD44 by rhabdomyosarcoma: a new prognostic marker?, BR J CANC, 80(5-6), 1999, pp. 918-921

Authors: Weiss, LM Chan, JKC MacLennan, K Warnke, RA

Citation: Lm. Weiss et al., Pathology of classical Hodgkin's disease, HODGKIN'S DISEASE, 1999, pp. 101-120